GlassScriptPhysician profile
Neeharika Repaka
NPI 1235427592
$5,979.27
in general payments reported to CMS, 2019-2025
44 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $442 · 2021: $168 · 2022: $509 · 2023: $1,001 · 2024: $1,207 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,274.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,052.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $643.70 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $450.73 | 2019-2025 | Korlym |
| Abbvie INC. | $431.79 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $329.53 | 2019-2025 | Unithroid |
| Insulet Corporation | $283.20 | 2019-2025 | Omnipod |
| Medtronic, INC. | $223.71 | 2023-2024 | Minimed 780g, Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $212.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $181.70 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $177.25 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $170.82 | 2023-2025 | Strensiq |
| Amgen INC. | $168.58 | 2019-2025 | Tepezza, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.27 | 2019-2023 | Jardiance, Tradjenta |
| Dexcom, INC. | $117.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $115.95 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $112.19 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $102.66 | 2019-2023 | Tymlos |
| Antares Pharma, INC. | $99.76 | 2019-2025 | Xyosted |
| Abbott Laboratories | $96.12 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Ibsa Pharma INC. | $95.24 | 2023-2025 | Licart, Tirosint, Flector |
| Shire North American Group INC | $86.32 | 2019 | |
| Recordati_rare_diseases_inc. | $68.86 | 2023-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $68.25 | 2019-2020 | |
| Horizon Therapeutics Plc | $54.86 | 2019-2023 | |
| Amphastar Pharmaceuticals, INC. | $52.81 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $45.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.63 | 2024 | |
| Ascendis Pharma Endocrinology INC | $29.06 | 2025 | Yorvipath |
| Medtronic Minimed, INC. | $27.87 | 2019 | |
| Madrigal Pharmaceuticals | $23.86 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $22.43 | 2024 | Veozah |
| Kyowa Kirin, INC. | $20.93 | 2023 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $20.77 | 2025 | |
| Valeritas, INC. | $20.60 | 2019 | |
| Tandem Diabetes Care, INC. | $20.49 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Azurity Pharmaceuticals, INC. | $18.94 | 2023 | Adthyza |
| Acella Pharmaceuticals, LLC | $18.78 | 2025 | NP Thyroid 60 |
| Eisai INC. | $18.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.48 | 2020 | |
| Sequel Med Tech, LLC | $17.38 | 2025 | Twiist |
| Halozyme INC | $16.83 | 2023 | |
| Pfizer INC. | $16.77 | 2019 | |
| Tolmar, INC. | $13.16 | 2024 | |
| Cequr Corporation | $12.69 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeharika Repaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.